French vaccine maker Valneva is expanding trials of a Covid-19 vaccine candidate called VLA2001, and remains in talks with the European Commission over a potential contract, the company said on Sept. 23.
Valneva SE commenced rolling submission for initial approval of the company’s COVID-19 vaccine candidate VLA2001 with the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
Valneva SE announced the initiation of a further Phase 3 trial (VLA2001-304) for the company’s inactivated, adjuvanted Covid-19 vaccine candidate VLA2001.
Pipeline Report 2021: COVID-19 Edition
Annual Reports, AstraZeneca, Bayer, BioNTech, BNT162b2 (Pfizer and BioNTech), CanSino Biologics, Clinical Trials, Clover Biopharmaceuticals, Clover Biopharmaceuticals, Coronavirus Disease 2019 (COVID-19), COVID-19 Vaccines, CureVac, Eli Lilly, February 2021, Gamaleya Research Institute, Gilead, GlaxoSmithKline, Immunology Companies, Inovio Pharmaceuticals, Janssen, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Med Ad News, Merck, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Novavax, Oxford University, Pfizer, R&D, Sanofi, Sinopharm, Sinovac, Special Reports, Sputnik V vaccine, The Lancet, Therapeutics, Top 10 Pipelines, Top 10 Pipelines To Watch, Vaccine Companies, Valneva, Vir BiotechnologyAs the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.